Skip to content

No results found

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

BGLC BioNexus Gene Lab Corp Common stock
$2.26 0.00% 0.00
Notify me if price changes either direction
Interactive Brokers Logotype

Buy BGLC stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 5.3M
Enterprise value 1.4M
Trailing PE -2.5
PEG Ratio 0.052913379483454
Enterprise to EBITDA -0.584
Enterprise to revenue 0.144
Price to book MRQ 0.59040594
Price to sales TTM 0.5594283

Financials

Fiscal Year Ends 2024-12-31
Most Recent Quarter (MRQ) 2025-09-30
Revenue (TTM) 9.5M
EBITDA -2333958
Diluted EPS TTM -1.28
Total Cash (MRQ) 2.9M
Current ratio (MRQ) 8.299
Operating Cash Flow (TTM) -2721241

BGLC trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent BGLC News

Home

No results found

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.